The ILP-technology is based on deploying chemokines, which until now have been regarded too unstable to be suitable as therapeutics. Ilya Pharma has overcome this problem by letting live lactic acid bacteria produce and deliver the human therapeutic chemokines on site in wounds in skin or e.g in the intestine acting like small bioreactors.